Department of Reproductive Medicine, Hainan Modern Women and Children's Hospital, Haikou, China.
Department of Medical Genetics, Haikou Hospital of Maternal and Child Health, Haikou, China.
Ann Palliat Med. 2022 Jan;11(1):352-362. doi: 10.21037/apm-21-3638.
Polycystic ovary syndrome (PCOS) is a common endocrine disease leading to infertility in women of childbearing age. Adjuvant therapy with Jinfeng pills (a traditional Chinese medicine) can increase ovarian blood flow, regulate female endocrine levels, and achieve good therapeutic effect. A systematic review and meta-analysis were conducted to examine the efficacy and safety of Jinfeng pills.
The PubMed (2000 to August 2021), Excerpta Medica Database (2000 to August 2021), Chinese Biomedical Literature (2000 to August 2021), and China National Knowledge Infrastructure (2000 to August 2021) databases were searched. All patients with PCOS were included in the randomized controlled study of Jinfeng pills combined with an adjuvant Western medicine treatment. After screening and a risk of bias assessment, Stata16.0 software was used for the analysis.
A total 7 of articles (comprising 691 patients; 26-83 participants per group) were included in the meta-analysis. The meta-analysis showed that the effective rate the experimental group treated with Jinfeng pills combined with adjuvant Western medicine was higher than that of the control group treated with Western medicine only [relative risk (RR) =1.15, 95% confidence interval (CI): 1.03 to 1.28; P=0.015]. After treatment, the follicle-stimulating hormone level of the experimental group was significantly lower than that of the control group [mean difference (MD) =-5.10, 95% CI: -7.95 to -2.24; P=0.0005], the estradiol level of the experimental group was significantly higher than that of the control group (MD =10.74, 95% CI: 4.19 to 17.29; P=0.001), the testosterone level of the experimental group was significantly lower than that of the control group (MD =-1.17, 95% CI: -2.09 to -0.25; P=0.01), and the pregnancy rate of the experimental group was significantly higher than that of the control group (RR =1.36, 95% CI: 1.13 to 1.64; Z=3.183; P=0.001).
The therapeutic effect of Jinfeng pills combined with Western medicine in treating PCOS was better than that of Western medicine alone, and there was no increase in adverse reactions.
多囊卵巢综合征(PCOS)是一种常见的导致育龄妇女不孕的内分泌疾病。金凤丸(一种中药)辅助治疗可以增加卵巢血流,调节女性内分泌水平,达到良好的治疗效果。系统评价和荟萃分析旨在研究金凤丸的疗效和安全性。
检索 PubMed(2000 年至 2021 年 8 月)、Excerpta Medica 数据库(2000 年至 2021 年 8 月)、中国生物医学文献数据库(2000 年至 2021 年 8 月)和中国国家知识基础设施数据库(2000 年至 2021 年 8 月),纳入金凤丸联合西药辅助治疗 PCOS 的随机对照研究。经过筛选和偏倚风险评估后,使用 Stata16.0 软件进行分析。
共有 7 篇文章(共 691 例患者;每组 26-83 例)纳入荟萃分析。荟萃分析显示,金凤丸联合西药辅助治疗组的有效率高于单纯西药对照组[相对风险(RR)=1.15,95%置信区间(CI):1.03 至 1.28;P=0.015]。治疗后,实验组的卵泡刺激素水平明显低于对照组[均数差(MD)=-5.10,95%CI:-7.95 至-2.24;P=0.0005],实验组的雌二醇水平明显高于对照组(MD=10.74,95%CI:4.19 至 17.29;P=0.001),实验组的睾酮水平明显低于对照组(MD=-1.17,95%CI:-2.09 至-0.25;P=0.01),实验组的妊娠率明显高于对照组(RR=1.36,95%CI:1.13 至 1.64;Z=3.183;P=0.001)。
金凤丸联合西药治疗 PCOS 的疗效优于单纯西药,且不良反应无增加。